Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term
safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary
Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of
double-blind treatment.